SymBio Pharmaceuticals Limited's nighttime PTS price was ¥63.1, trading 1.41% below the Tokyo Stock Exchange closing price. As part of its August financing activity, the company disclosed the issuance of its 70th and 71st stock acquisition rights and its 2nd straight bond issue, and financing of approximately ¥6.77 billion was reported on 18 August.
SymBio Pharmaceuticals Limited's nighttime PTS trading price was ¥63.1 as of 22:30, down ¥0.9, or 1.41%, from the previous close. Trading volume during the same period was 1,200 shares, with a trading value of ¥76 thousand.
On 17 August, the company disclosed the issuance of its 70th and 71st stock acquisition rights and its 2nd straight bond issue. The related financing activity appears to have affected the share price shortly afterward. The amount raised, reported on 18 August, was approximately ¥6.77 billion.
According to the earnings information, during the interim period of the fiscal year ending December 2026, revenue fell 27.3% year on year to approximately ¥470 million, research and development expenses increased 89.5% to approximately ¥3.0 billion, and the interim net loss reached approximately ¥3.62 billion. The company remained in a negative net worth position at the end of the interim period, and uncertainty was identified regarding the going concern assumption.